LL-37: doses reported in published research

Sources checked 2026-10-07 · 2 cited studies (2 human, 0 animal, 0 cell culture) · 1 registered trial

LL-37 is a 37-amino-acid human antimicrobial peptide (the active fragment of cathelicidin). It has been tested in people as a topical solution on chronic leg ulcers and by intratumoral administration in melanoma.

Human data: two randomized placebo-controlled trials of topical LL-37 on venous leg ulcers, and a phase 1/2 intratumoral melanoma trial with results posted on ClinicalTrials.gov.

Studies in people (2)

Human 34 adults with venous leg ulcers, first-in-human randomized double-blind placebo-controlled trial

Dose as reported: 0.5, 1.6 or 3.2 mg/mL (separate groups)
Route: Topical, applied to the ulcer
Frequency / duration: Twice weekly for 4 weeks

Source wording: This first-in-man trial included 34 participants with VLUs and comprised a 3-week, open-label, run-in period on placebo, followed by a 4-week randomized double-blind treatment phase with twice weekly applications of LL-37 (0.5, 1.6, or 3.2 mg/mL) or placebo, and a 4-week follow-up.

Grönberg A, Mahlapuu M, Ståhle M et al.. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 2014. PubMed PMID 25041740 ↗

Human 148 adults with venous leg ulcers, phase 2b randomized double-blind placebo-controlled trial (HEAL LL-37)

Dose as reported: 0.5 or 1.6 mg/mL (separate groups)
Route: Topical
Frequency / duration: Not stated in the abstract

Source wording: The study had three arms, consisting of two groups treated with LL-37 at concentrations of 0.5 or 1.6 mg/mL, and a placebo cohort. LL-37 for topical administration

Mahlapuu M, Sidorowicz A, Mikosinski J et al.. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen 2021. PubMed PMID 34687253 ↗

Registered trials (1)

From ClinicalTrials.gov records. Registry entries describe planned designs; they are not published results.

Registered trial (no published results) Adults with melanoma skin metastases, phase 1/2; completed, results posted

Dose as reported: Starting dose 250 µg per tumour
Route: Intratumoral
Frequency / duration: Every 7 days for up to 8 weeks

Source wording: Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.

Intratumoral Injections of LL37 for Melanoma. ClinicalTrials.gov registry record. NCT02225366 ↗

Half-life

No half-life value was found in the sources reviewed for this page.

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.